miR‑329 inhibits papillary thyroid cancer progression via direct targeting WNT1

Wu,Liang; Pei,Fulai; Men,Xiaojuan; Wang,Kai; Ma,Deliang

doi:10.3892/ol.2018.9102

miR‑329 inhibits papillary thyroid cancer progression via direct targeting WNT1

Authors:
- Liang Wu
- Fulai Pei
- Xiaojuan Men
- Kai Wang
- Deliang Ma
View Affiliations

Affiliations: Department of Oncology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China, Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: July 6, 2018 https://doi.org/10.3892/ol.2018.9102
Pages: 3561-3568
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulated microRNA‑329 (miR‑329) serves an important role in the progression of certain types of tumor. However, the exact function and mechanisms of miR‑329 in papillary thyroid cancer (PTC) remain unknown. The present study investigated the function and mechanisms of miR‑329 in regulating PTC cell progression. The results revealed that the expression of miR‑329 was significantly downregulated in PTC tissues and cell lines compared with adjacent normal tissues and a human immortalized follicular cell line. miR‑329 mimics notably decreased PTC cell proliferation, colony formation and WNT1 expression in vitro, as well as suppressing PTC tumor growth in vivo. In addition, luciferase assays determined that miR‑329 was able to directly bind with the 3'untranslated region of WNT1. Furthermore, short interfering RNA‑WNT1‑induced downregulation of WNT1, which demonstrated similar effects to miR‑329 overexpression. WNT1 overexpression rescued the tumor suppressive effects of miR‑329 in PTC cells. The present study provided new insights into the role of miR‑329 in PTC progression and suggests the potential application of miR‑329 as a therapy for PTC.

View Figures

View References

1	Liebner DA and Shah MH: Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gonzalez-Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG, Gómezpalacio-Gastelum M, Molina-Frechero N and Salazar-Rodriguez S: Papillary thyroid carcinoma: Differential diagnosis and prognostic values of its different variants: Review of the literature. ISRN Oncol. 2011:9159252011.PubMed/NCBI
3	Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z1, Teng W, Musholt TJ, et al: Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016. View Article : Google Scholar : PubMed/NCBI
4	Orang Valinezhad A, Safaralizadeh R and Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics. 2014:9706072014.PubMed/NCBI
5	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wang X, Lu X, Zhang T, Wen C, Shi M, Tang X, Chen H, Peng C, Li H, Fang Y, et al: mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Oncotarget. 7:21441–21453. 2016.PubMed/NCBI
7	Yang H, Li Q, Zhao W, Yuan D, Zhao H and Zhou Y: miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett. 588:192–197. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu D, Feng J, Yang D, Song L and Yan X: MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol. 33:3689–3699. 2013. View Article : Google Scholar : PubMed/NCBI
9	Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY and de Li J: Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget. 7:21510–21526. 2016.PubMed/NCBI
10	Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J and Feng F: By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 6:17559–17569. 2015.PubMed/NCBI
11	Shiah SG, Hsiao JR, Chang WM, Chen YW, Jin YT, Wong TY, Huang JS, Tsai ST, Hsu YM and Chou ST: Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. Cancer Res. 74:7560–7572. 2014. View Article : Google Scholar : PubMed/NCBI
12	Xiao B, Tan L, He B, Liu Z and Xu R: miRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. J Transl Med. 11:1722013. View Article : Google Scholar : PubMed/NCBI
13	Li W, Liang J, Zhang Z, Lou H, Zhao L, Xu Y and Ou R: MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer. Oncol Rep. 37:2743–2750. 2017. View Article : Google Scholar : PubMed/NCBI
14	Saiselet M, Floor S, Tarabichi M, Dom Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell lines: An overview. Front Endocrinol (Lausanne). 3:1332012.PubMed/NCBI
15	Benad P, Rauner M, Rachner TD and Hofbauer LC: The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer letters. 312:101–108. 2011. View Article : Google Scholar : PubMed/NCBI
16	Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M and Lamparska-Przybysz M: Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 17:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK and Lamparska-Przybysz M: Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol Ther. 7:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wang JM, Huang FC, Kuo MH, Wang ZF, Tseng TY, Chang LC, Yen SJ, Chang TC and Lin JJ: Inhibition of cancer cell migration and invasion through suppressing the Wnt1-mediating signal pathway by G-quadruplex structure stabilizers. J Biol Chem. 289:14612–14623. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sasaya K, Sudo H, Maeda G, Kawashiri S and Imai K: Concomitant loss of p120-catenin and β-catenin membrane expression and oral carcinoma progression with E-cadherin reduction. PLoS One. 8:e697772013. View Article : Google Scholar : PubMed/NCBI